Basilea CEO Sees Blockbuster Potential for Antifungal Drug
This article is for subscribers only.
Basilea Pharmaceutica AG, an antiobiotic producer with a market value exceeding $1 billion, sees a chance for its drug isavuconazole to reach sales of about $1 billion if it gets regulatory approval in the U.S. and Europe.
“There is a significant medical need for isavuconazole due to limited treatment options,” Chief Executive Officer Ronald Scott said in an interview today. “We don’t provide forecasts for our drug sales,” he said, adding that he sees Pfizer Inc’s treatment voriconazole as a benchmark.